衰变加速因子在复发性流产中的表达
Expression of the Decay Acceleration Factor in Recurrent Abortion
DOI: 10.12677/ACM.2022.124500, PDF, 下载: 237  浏览: 302 
作者: 赵 威：青岛大学，山东 青岛；刘建新*：青岛大学附属医院，山东 青岛
关键词: 补体系统；补体调节蛋白；CD55；Crry；复发性流产；Complement System； Complement Regulatory Protein； CD55； Crry； Recurrent Pregnancy Loss
摘要: 完整的补体系统可改善胎盘的发育和功能，对维持宿主防御和胎儿存活至关重要。补体调节在妊娠早期发挥重要作用，一定程度的补体激活保证妊娠的正常发生。妊娠期间，妊娠过程靠母体的免疫抑制状态保证，补体激活的适当抑制则成为了妊娠所必需。正常妊娠的胎盘滋养层细胞在整个妊娠期高表达补体调节蛋白衰变加速因子(decay-accelerating factor, DAF, CD55)、膜辅助蛋白(membrane cofactor protein, MCP)和CD59，可阻止母体补体的过度激活对胚胎的损伤。部分研究显示，CD55表达受损可能会产生免疫异常环境，破坏胚胎植入和妊娠早期发育。本次我们旨在分析补体系统中的补体调节蛋白CD55与复发性流产之间的潜在关联。
Abstract: A complete complement system can improve placental development and function, and is essential for maintaining host defense and fetal survival. Complement regulation plays an important role in the early pregnancy, and a certain degree of complement activation ensures the normal pregnancy. During pregnancy, it is guaranteed by the maternal immunosuppression state, and the proper inhibition of complement activation becomes necessary for pregnancy. The placental trophoblast cells in normal pregnancy highly express decay-accelerating factor (DAF, CD55), membrane cofactor protein (MCP) and CD59, which can prevent the overactivation of maternal complement. Some studies have shown that impaired CD55 expression may produce an abnormal immune environment that disrupts embryo implantation and early pregnancy development. This time we aimed to analyze the potential association between the complement regulatory protein CD55 in the complement system and recurrent abortion.
文章引用：赵威, 刘建新. 衰变加速因子在复发性流产中的表达[J]. 临床医学进展, 2022, 12(4): 3454-3459. https://doi.org/10.12677/ACM.2022.124500

参考文献

[1] [1]自然流产诊治中国专家共识编写组, 赵爱民. 自然流产诊治中国专家共识(2020年版) [J]. 中国实用妇科与产科杂志, 2020, 36(11): 1082-1090.
[2] Practice Committee of the American Society for Reproductive Medicine (2012) Evaluation and Treatment of Recurrent Pregnancy Loss: A Committee Opinion. Fertility and Sterility, 98, 1103-1111.
https://doi.org/10.1016/j.fertnstert.2012.06.048
[3] RCOG (2011) The Investigation and Treatment of Couples with Recurrent First-Trimester and Second-Trimester Miscarriage. Green-Top Guideline No. 17.
[4] Jaslow, C., Carney, J. and Kutteh, W. (2010) Diagnostic Factors Identified in 1020 Women with Two versus Three or More Recurrent Pregnancy Losses. Fertility and Sterility, 93, 1234-1243.
https://doi.org/10.1016/j.fertnstert.2009.01.166
[5] Tincani, A., Cavazzana, I., Ziglioli, T., et al. (2010) Complement Activation and Pregnancy Failure. Clinical Reviews in Allergy & Immunology, 39, 153-159.
https://doi.org/10.1007/s12016-009-8183-5
[6] Palomino, W.A., Tayade, C., Argandoña, F., et al. (2018) The Endometria of Women with Endometriosis Exhibit Dysfunctional Expression of Complement Regulatory Proteins during the Mid Secretory Phase. Journal of Reproductive Immunology, 125, 1-7.
https://doi.org/10.1016/j.jri.2017.10.046
[7] Girardi, G., Lingo, J.J., Fleming, S.D. and Regal, J.F. (2020) Essential Role of Complement in Pregnancy: From Implantation to Parturition and beyond. Frontiers in Immunology, 11, Article No. 1681.
https://doi.org/10.3389/fimmu.2020.01681
[8] 苏小玲, 赵爱民, 林其德. 补体异常激活在复发性流产中的作用[J]. 国际妇产科学杂志, 2013, 40(4): 353-357.
[9] Dho, S.H., Lim, J.C. and Kim, L.K. (2018) Beyond the Role of CD55 as a Complement Component. Immune Network, 18, e11.
https://doi.org/10.4110/in.2018.18.e11
[10] Holmes, C.H., Simpson, K.L., Okada, H., et al. (1992) Complement Regulatory Proteins at the Feto-Maternal Interface during Human Placental Development: Distribution of CD59 by Comparison with Membrane Cofactor Protein (CD46) and Decay Accelerating Factor (CD55). European Journal of Immunology, 22, 1579-1585.
https://doi.org/10.1002/eji.1830220635
[11] Regal, J.F., Gilbert, J.S. and Burwick, R.M. (2015) The Complement System and Adverse Pregnancy Outcomes. Molecular Immunology, 67, 56-70.
https://doi.org/10.1016/j.molimm.2015.02.030
[12] Xu, C., Mao, D., Holers, V.M., et al. (2000) A Critical Role for Murine Complement Regulator Crry in Fetomaternal Tolerance. Science, 287, 498-501.
https://doi.org/10.1126/science.287.5452.498
[13] Holers, V.M., Girardi, G., Mo, L., et al. (2002) Complement C3 Activation Is Required for Antiphospholipid Antibody-Induced Fetal Loss. The Journal of Experimental Medicine, 195, 211-220.
https://doi.org/10.1084/jem.200116116
[14] Caucheteux, S., Kanellopoulos-Langevin, C. and Ojcius, D. (2003) At the Innate Frontiers between Mother and Fetus: Linking Abortion with Complement Activation. Immunity, 18, 169-172.
https://doi.org/10.1016/S1074-7613(03)00028-1
[15] Young, S.L., Lessey, B.A., Fritz, M.A., et al. (2002) In Vivo and in Vitro Evidence Suggest that HB-EGF Regulates Endometrial Expression of Human Decay-Accelerating Factor. The Journal of Clinical Endocrinology & Metabolism, 87, 1368-1375.
https://doi.org/10.1210/jcem.87.3.8350
[16] Zhang, D., Sun, C., Ma, C., et al. (2012) Data Mining of Spatial-Temporal Expression of Genes in the Human Endometrium during the Window of Implantation. Reproductive Sciences, 19, 1085-1098.
https://doi.org/10.1177/1933719112442248
[17] Kaul, A., Nagamani, M. and Nowicki, B. (1995) Decreased Expression of Endometrial Decay Accelerating Factor (DAF), a Complement Regulatory Protein, in Patients with Luteal Phase Defect. American Journal of Reproductive Immunology, 34, 236-240.
https://doi.org/10.1111/j.1600-0897.1995.tb00947.x
[18] Wang, L., Zhang, W. and Guan, H.Y. (2018) Decay-Accelerating Factor Promotes Endometrial Cells Proliferation and Motility under Ovarian Hormone Stimulation. Reproductive Biology, 18, 225-235.
https://doi.org/10.1016/j.repbio.2018.07.004
[19] Palomino, W.A., Aguirre, C., Argandoña, F., et al. (2017) Abnormal Endometrial Expression of Complement Regulatory Protein Decay Accelerating Factor in Women with Recurrent Implantation Failure in Cycles of Assisted Reproduction. Placenta, 51, 120.
https://doi.org/10.1016/j.placenta.2017.01.076
[20] 肖世金, 赵爱民, 鲍世民. 补体过度激活与自身免疫型复发性流产的关系[J]. 上海交通大学学报(医学版), 2011, 31(8): 1125-1128.
[21] 王芳. 补体激活在抗磷脂综合征中的作用[J]. 中国医疗前沿, 2010, 5(16): 19+30.

为你推荐